Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.41
Bid: 1.40
Ask: 1.42
Change: 0.00 (0.00%)
Spread: 0.02 (1.429%)
Open: 1.41
High: 0.00
Low: 0.00
Prev. Close: 1.41
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

12 Jan 2022 08:05

Edison Investment Research Limited Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment 12-Jan-2022 / 08:05 GMT/BST


 

London, UK, 12 January 2021

 

RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment

RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW), which was founded in 2009 by Dr Roderick Wong. It has an innovative approach, focusing on attractive individual assets rather than on companies, so it engages across the corporate lifecycle, from business formations through to investing in much larger listed biotech and medtech companies. RTW is focused on identifying and developing next-generation therapies to significantly improve patients' lives. Since launch, RTWVF's number of investments in private companies has accelerated and the manager is very excited by the global opportunities available.

 

RTWVF provides investors with broad exposure to the global biotech (c 85% of the fund) and medtech (c 15%) sectors. Since inception in late October 2019, the fund has outpaced the performance of both small- and large-cap biotech indices. Its approach of being science-based and a full lifecycle investor, including early-stage, means that the manager is constantly adding to its knowledge bank. RTWVF is prepared to build businesses around attractive assets and supports investee companies as they mature, via a range of financing options. Holdings in private companies are often maintained following their initial public offerings (IPOs) to ensure maximum value is realised, while RTWVF also invests in companies that are already public. RTW has announced it is setting up regional offices in the UK and Shanghai, which should broaden the fund's opportunity set.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Sarah Godfrey +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1267706 12-Jan-2022 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
13th Nov 20206:22 pmRNSAnnouncement of Share Issuance
13th Nov 20207:00 amRNSNet Asset Value(s)
10th Nov 20209:26 amRNSHolding(s) in Company
9th Nov 20202:00 pmRNSNew Investment in Prometheus Biosciences
2nd Nov 20207:00 amRNSTotal Voting Rights
28th Oct 20201:25 pmRNSHolding(s) in Company
19th Oct 20207:01 amRNSTarsus Pharmaceuticals Prices $88 Million IPO
19th Oct 20207:00 amRNSQuarterly Update
16th Oct 20205:19 pmRNSIssue of Equity
14th Oct 20202:31 pmRNSAnnouncement of Share Issuance
14th Oct 20207:00 amRNSNet Asset Value(s)
5th Oct 20207:00 amRNSC4 Therapeutics Prices $182 Million IPO
2nd Oct 20207:00 amRNSPulmonx Prices $190 Million IPO
28th Sep 20204:13 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSInterim Report for the period ended 30 June 2020
21st Sep 20207:00 amRNSAthira Pharma Prices $204.0 Million IPO
15th Sep 20207:00 amRNSNet Asset Value(s)
14th Sep 20201:00 pmRNSSeries B Financing Round in NiKang Therapeutics
2nd Sep 20207:00 amRNSNotice of Interim Report
1st Sep 20207:00 amRNSTotal Voting Rights
17th Aug 20205:16 pmRNSIssue of Equity
14th Aug 20202:01 pmRNSAnnouncement of Share Issuance
14th Aug 20207:00 amRNSNet Asset Value(s)
12th Aug 20207:00 amRNSPortfolio Company Update
3rd Aug 20207:00 amRNSTotal Voting Rights
28th Jul 20206:25 pmRNSHolding(s) in Company
27th Jul 20207:00 amRNSiTeos Therapeutics Prices $201 Million IPO
23rd Jul 202012:00 pmRNSNew Investment in Milestone Pharmaceuticals
22nd Jul 20201:00 pmRNSSeries D Financing in Encoded Therapeutics
21st Jul 20207:00 amRNSQuarterly Update
17th Jul 202011:44 amRNSIssue of Equity - Replacement Announcement
17th Jul 20207:00 amRNSIssue of Equity
16th Jul 20206:08 pmRNSAnnouncement of further Share Issuance
16th Jul 20207:00 amRNSIssue of Equity
15th Jul 20207:00 amRNSNet Asset Value(s)
25th Jun 20206:08 pmRNSResult of AGM
22nd Jun 20201:59 pmRNSAGM Statement
16th Jun 20201:15 pmRNSSeries B Financing in C4 Therapeutics
16th Jun 20207:00 amRNSUpdate on Avidity Biosciences IPO
12th Jun 20209:33 amRNSAvidity Biosciences Prices $259.2 Million IPO
12th Jun 20207:00 amRNSNet Asset Value(s)
4th Jun 202012:30 pmRNSSeries B Financing in Athira Pharma
1st Jun 20207:00 amRNSTotal Voting Rights
21st May 20204:00 pmRNSNotice of AGM
19th May 20205:40 pmRNSIssue of Equity
18th May 20207:00 amRNSAnnouncement of Share Issuance
14th May 20207:00 amRNSNet Asset Value(s)
1st May 20207:00 amRNSTotal Voting Rights
28th Apr 20204:36 pmRNSDirector/PDMR Shareholding
28th Apr 20204:29 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.